Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: DNA vaccines - Inovio

Drug Profile

Research programme: DNA vaccines - Inovio

Alternative Names: Chikungunya virus DNA vaccine - Inovio; CHIKV vaccine - Inovio; Cytomegalovirus DNA vaccine - Inovio; dMab HIV - Inovio; DNA vaccine against HIV clade C - Inovio; INO 5400; MAGE-A DNA vaccine; Malaria vaccine - Inovio; Smallpox vaccine - Inovio; SynCon WT1 cancer immunotherapy

Latest Information Update: 01 Feb 2018

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inovio Pharmaceuticals
  • Developer Drexel University College of Medicine; Inovio Pharmaceuticals
  • Class AIDS vaccines; Bacterial vaccines; Cancer vaccines; DNA vaccines; Hepatitis C vaccines; Parasitic vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Smallpox

Highest Development Phases

  • Discontinued Cancer; Chikungunya virus infections; Clostridium difficile infections; Cytomegalovirus infections; Human papillomavirus infections; Malaria; Malignant melanoma; Smallpox; Tuberculosis

Most Recent Events

  • 01 Feb 2018 Discontinued - Preclinical for Cancer in USA (Parenteral)
  • 01 Feb 2018 Discontinued - Preclinical for Chikungunya virus infections in USA (IM)
  • 01 Feb 2018 Discontinued - Preclinical for Clostridium difficile infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top